Compare Enbridge Inc (ENB) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Repligen Corporation Common Stock — how do they compare? Enbridge Inc trades at $47.52 (market cap $105.42B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Enbridge Inc is far larger — about 9.5× Repligen Corporation Common Stock's market cap, and Enbridge Inc pays a 5.9% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 92 Days and Repligen Corporation Common Stock for 0 Days on average.
| ENB | RGEN | |
|---|---|---|
Market Cap | $105.42B | $11.14B |
Volume | 3,621,007 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $58.04 | $194.57 |
52-Week Low | $45.23 | $102.87 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $187.30B | $11.02B |
Dividend Yield | 5.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $47.35, up 0.85% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with three consecutive quarterly earnings beats and a 6% dividend yield. Revenue grew to $65.19 billion in 2025 with net income of $7.49 billion, though 2026 projections show margin compression. Recent news highlights ENB's expansion into European renewables and Permian Basin acquisitions as growth drivers.
ENB offers income investors a stable 6% yield with growth potential from its $41 billion project backlog, but faces headwinds from rising interest rates and potential oil price volatility. Analyst consensus is balanced with 48% buy ratings and a $61.63 price target suggesting 30% upside, though technical indicators remain cautious near-term.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
